Repaglinide 2 mg (Generic)

Product Overview

Repaglinide 2 mg (Generic) is a prescription oral antidiabetic medication indicated for the management of type 2 diabetes mellitus. Manufactured by Novo Nordisk India this product is supplied in a strip containing 15 tablets each containing 2 milligrams of repaglinide. The tablets are film coated for ease of swallowing and are intended for daily use as part of a comprehensive treatment plan that includes diet exercise and glucose monitoring. Pack sizes of 30 60 and 90 tablets are available allowing patients and clinicians to select the most appropriate supply based on treatment duration and clinical response. The medication should be stored at room temperature protected from moisture and heat and kept out of reach of children

What is Repaglinide 2 mg (Generic)?

Repaglinide belongs to the class of meglitinides a group of drugs that lower blood glucose by stimulating insulin release from pancreatic beta cells in a glucose dependent manner. Unlike sulfonylureas repaglinide’s action is rapidly reversible which means its hypoglycemic effect diminishes quickly when glucose levels fall reducing the risk of prolonged low blood sugar. The generic formulation contains the same active ingredient as the branded product but is typically offered at a lower cost making it accessible to a broader patient population. Each tablet delivers exactly 2 milligrams of repaglinide a strength that is commonly used as a starting dose or as part of a titration regimen tailored to the individual’s renal function and glycemic control

Uses and Benefits

The primary use of repaglinide 2 mg is to improve post prandial glucose excursions in adults with type 2 diabetes who have not achieved adequate control with lifestyle modification alone. When taken before meals the drug helps blunt the spike in blood sugar that occurs after eating thereby contributing to a more stable overall glycemic profile. Clinical studies have demonstrated that repaglinide can reduce HbA1c by approximately 0.5 to 1 percent when used as monotherapy or in combination with metformin or other oral agents. Additional benefits include its compatibility with a flexible dosing schedule as it can be taken up to three times daily before the three main meals allowing patients to adapt the regimen to varying meal patterns and social circumstances

How It Works

Repaglinide acts by binding to the sulfonylurea receptor SUR1 on the surface of pancreatic beta cells leading to closure of ATP sensitive potassium channels and subsequent calcium influx. This sequence triggers insulin granule exocytosis in a glucose dependent fashion meaning that insulin release is proportional to the current glucose concentration. Because the drug’s effect wanes rapidly as glucose levels decline it minimizes the chance of insulin secretion when glucose is low which translates into a lower incidence of hypoglycemia compared with longer acting sulfonylureas. The rapid onset within 30 minutes and short duration about 4 to 6 hours make repaglinide particularly suited for controlling the glucose rise that follows a meal According to the National Institutes of Health NIH repaglinide belongs to the meglitinide class

Dosage Guidelines

The recommended starting dose of repaglinide 2 mg is typically one tablet taken before each main meal and the dose may be adjusted based on the patient’s response and risk of hypoglycemia. Physicians often begin with a lower dose such as 0.5 mg or 1 mg and titrate upward every 1 to 2 weeks until the desired post prandial glucose target is achieved with a maximum daily dose generally not exceeding 16 mg divided across three doses. It is essential that patients follow the dosing instructions provided by their healthcare provider as factors such as renal impairment hepatic disease and concomitant medications can influence the appropriate dose. Tablets should be swallowed whole with water and should not be crushed split or chewed

Side Effects

Like all medications repaglinide can cause adverse effects although most are mild and transient. The most commonly reported side effects include headache dizziness upper respiratory tract infections and mild hypoglycemia which may manifest as shakiness sweating or irritability if blood glucose falls too low. Less frequent but clinically important events include hepatic enzyme elevations skin reactions such as rash or pruritus and rare instances of pancreatitis. Patients should be advised to monitor for signs of low blood sugar especially when repaglinide is used in combination with other glucose lowering agents and to seek medical attention if symptoms persist or worsen Refer to the FDA label for detailed safety information

Warnings and Precautions

Repaglinide is contraindicated in patients with type 1 diabetes diabetic ketoacidosis or a history of hypersensitivity to the drug. Caution is advised in individuals with moderate to severe renal impairment as reduced clearance may increase the risk of hypoglycemia dose reduction is recommended in such cases. The medication should be used with care in patients with hepatic dysfunction since metabolism occurs primarily in the liver. It is also important to avoid concomitant use of certain drugs that may enhance the hypoglycemic effect such as other secretagogues or insulin unless closely monitored. Pregnant or breastfeeding women should only use repaglinide if the potential benefit justifies the potential risk and they should discuss this with their physician Consult MedlinePlus for additional guidance

Frequently Asked Questions

1. What is the difference between repaglinide and metformin? Repaglinide lowers post prandial glucose by stimulating insulin release while metformin primarily reduces hepatic glucose production and improves insulin sensitivity.
2. Can repaglinide be taken with food? It should be taken shortly before a meal; taking it without food may reduce its effectiveness.
3. How long does it take to see a reduction in HbA1c? Clinical trials show modest HbA1c decreases after 12 weeks of consistent use though individual response varies.
4. Is the generic version as effective as the branded product? Yes the generic contains the same active ingredient and is bioequivalent to the reference listed drug when taken as directed.
5. What should I do if I miss a dose? If you forget to take a dose before a meal simply skip it; do not double up to make up for the missed tablet.
6. Are there dietary restrictions while using repaglinide? No specific foods need to be avoided but the medication should be taken before meals for optimal effect.

These FAQs address common concerns and can help patients discuss treatment options with their healthcare provider Always consult your physician before making any changes to your medication regimen For more detailed information refer to the FDA label https://www.fda.gov/drugs and the National Institutes of Health https://www.nih.gov Additional resources are available on MedlinePlus https://medlineplus.gov/druginfo/meds/a682130.html and Drugs.com https://www.drugs.com/monograph/repaglinide.html